Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 21,040 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Heart Failure, Pulmonary Disease, Chronic Obstructive, Interstitial Lung Disease
Interventions: Virtual Nurse and Social Worker Palliative Care Team, Enhanced Implementation Support, Standard Implementation Support; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 4 more

Conditions: Glial Tumor of Brain, Diffuse Intrinsic Pontine Glioma, Glioma
Interventions: Gemcitabine, Tumor biopsy and blood draw; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 3 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Metastatic Pancreatic Cancer
Interventions: Albumin-bound paclitaxel (ABI-007), Gemcitabine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 861 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 90
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 71 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Self-Affirmation; Behavioral
Lead sponsor: Elizabeth Scharnetzki; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Westbrook, Maine

Conditions: Knee Osteoarthritis
Interventions: ROAM OA Single Upright Knee Brace, Ossur Unloader One Knee Brace or Standard of Care; Device
Lead sponsor: Rush University Medical Center; Other
Eligibility: 40 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gastroesophageal Reflux Disease
Interventions: Ursodeoxycholic Acid; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Neoplasms, Head and Neck
Interventions: Lapatinib, Chemoradiation, Placebo; Drug · Radiation · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 5
States / cities: Springfield, Illinois • St Louis, Missouri • New York, New York + 2 more

Conditions: Alcoholism
Interventions: Alcohol, Placebo; Other
Lead sponsor: Indiana University; Other
Eligibility: 21 Years to 27 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Dry Eye
Interventions: Artificial tears; Drug
Lead sponsor: Hom, Milton M., OD, FAAO; Individual
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Azusa, California

Conditions: Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders, Vision Disorder, Neurological Manifestations, Eye Diseases, Hereditary, Eye Diseases, Eye Disorders Congenital, Retinal Disease
Interventions: sepofarsen, Placebo IVT; Drug · Other
Lead sponsor: Laboratoires Thea; Industry
Eligibility: 6 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: San Francisco, California • Miami, Florida • Iowa City, Iowa + 2 more

Conditions: Menopausal Syndrome
Interventions: Estradiol (E2), Progesterone (P10) x90, Progesterone (P10) x10; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Ocular Graft Versus Host Disease
Interventions: Amniotic Fluid Eye Drops (AFED), Saline Solution; Biological · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: DS-3939a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Sarasota, Florida • Locust Grove, Georgia • Westwood, Kansas + 9 more

Conditions: Diabetes
Interventions: team-based care; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure, Congestive
Interventions: Teach to Goal (TTG), Brief Educational Intervention (BEI); Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 1 more

Conditions: Obesity
Interventions: Exenatide, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 12 Years to 19 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: Knowledge, Attitude
Interventions: RS+, Codeacademy; Behavioral
Lead sponsor: Mathematica Policy Research, Inc.; Other
Eligibility: Up to 17 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Oak Park, Illinois

Conditions: Cervical Spondylosis With Myelopathy
Interventions: Ventral (Front) decompression with Fusion, Dorsal (Back) Decompression with Fusion, Dorsal (back) Laminoplasty; Procedure
Lead sponsor: Lahey Clinic; Other
Eligibility: 45 Years to 80 Years
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 15
States / cities: San Francisco, California • Atlanta, Georgia • Kansas City, Kansas + 10 more

Conditions: Nephrolithiasis, Urinary Tract Infection (UTI), Sepsis
Interventions: Nitrofurantoin 100 MG, 7d, Gentamicin, 5mg/kg, Ampicillin 2g, Nitrofurantoin 100 mg, 48 hrs, Gentamicin, 80 mg, 7d, Gentamicin, 80 mg, 48hr; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Not listed
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Volunteers
Interventions: AdCOVID, Placebo; Biological · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Hialeah, Florida • Melbourne, Florida • Peoria, Illinois + 3 more

Conditions: Inflammation, Uveitis
Interventions: Fluocinolone Acetonide 0.59 mg, Fluocinolone Acetonide 2.1 mg; Procedure
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: One-lung Ventilation (OLV)
Interventions: Intracuff pressure measurement in one-lung ventilation during thoracic surgery; Procedure
Lead sponsor: Joseph D. Tobias; Other
Eligibility: Up to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pediatric Cancer, Animal-Assisted Activities
Interventions: Therapy Dog Visit; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 5 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Ovarian Carcinosarcoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions: Bevacizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib; Biological · Procedure · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 676
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 458 more

Search by objective public record fields.

Virtual Nurse and Social Worker Palliative Care Team to Improve Quality of Life in Veterans With Heart Failure or COPD

Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

Strategies to Improve Well-Being and Diabetes Management

ROAM OA: Functional and Patient Reported Outcomes Wearing a Knee Brace for Unicompartmental OA

Clinical Studies on Bile Acids in Barrett's Esophagus

Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)

Tear Osmolarity Over Time With Artificial Tears

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Early Menopause Hormone Treatment and Cognition

Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Comprehensive Intervention to Evaluate Outcomes AND Cost in Hospitalized Surgical Patients With Diabetes Mellitus (DM)

Educational Program for Various Health Literacy Levels to Improve the Health of Individuals With Heart Failure

Exenatide in Extreme Pediatric Obesity

Testing the Effectiveness of Relationship Smarts and the Effects of Enhanced Facilitator Training

Cervical Spondylotic Myelopathy Surgical Trial

Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant

Intracuff Pressure During One-lung Ventilation in Infants and Children

Helping Improve Pediatric Patient Outcomes

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer